Table 1 Sociodemographic and clinical characteristics of the patients included in the study
Characteristic | Phase I | Phase II | Phase III | Phase IV | Phase VI | |||||
|---|---|---|---|---|---|---|---|---|---|---|
(n = 20) | (n = 60) | (n = 149) | (n = 323) | (n = 54) | ||||||
n | % | n | % | n | % | n | % | n | % | |
Gender | ||||||||||
Male | 8 | 40.0 | 27 | 45.0 | 49 | 32.9 | 151 | 46.7 | 36 | 60.0 |
Female | 12 | 60.0 | 33 | 55.0 | 100 | 67.1 | 172 | 53.3 | 24 | 40.0 |
Age (years) | ||||||||||
<40 | 1 | 5.0 | 12 | 20.0 | 39 | 26.2 | 45 | 13.9 | 10 | 16.7 |
40–65 | 16 | 80.0 | 35 | 58.3 | 91 | 61.1 | 197 | 61.0 | 41 | 68.3 |
≥65 | 3 | 15.0 | 13 | 21.7 | 19 | 12.8 | 81 | 25.1 | 9 | 15.0 |
Educational level (years of formal schooling) | ||||||||||
Illiterate | 0 | 0 | 0 | 0 | 4 | 2.7 | 16 | 5.0 | 4 | 6.7 |
<8 | 5 | 25.0 | 23 | 38.3 | 56 | 37.6 | 145 | 44.9 | 27 | 45.0 |
8–11 | 6 | 30.0 | 16 | 26.7 | 26 | 17.4 | 84 | 26.0 | 24 | 44.0 |
>11 | 9 | 45.0 | 21 | 35.0 | 63 | 42.3 | 78 | 24.1 | 5 | 8.3 |
Family income (expressed as multiples of the minimum wage) | ||||||||||
≤1 | 3 | 15.0 | 14 | 25.0 | 29 | 19.7 | 52 | 17.9 | 23 | 38.3 |
1–2 | 8 | 40.0 | 11 | 19.6 | 51 | 34.7 | 63 | 21.7 | 18 | 30.0 |
2.1–3 | 4 | 20.0 | 12 | 21.4 | 26 | 17.7 | 49 | 16.9 | 10 | 16.7 |
>3 | 5 | 25.0 | 19 | 33.9 | 41 | 27.9 | 126 | 43.4 | 7 | 12.0 |
Missing | 0 | 4 | 2 | 33 | 2 | |||||
Brazilian region of origin | ||||||||||
Southeast | 14 | 70.0 | 42 | 70.0 | 106 | 71.1 | 257 | 79.6 | 43 | 71.7 |
Southern | 0 | 0 | 1 | 1.7 | 1 | 0.7 | 1 | 0.3 | 0 | 0.0 |
Northern | 1 | 5.0 | 4 | 6.7 | 7 | 4.7 | 22 | 6.8 | 7 | 11.7 |
Midwest | 5 | 25.0 | 13 | 21.7 | 34 | 22.8 | 40 | 12.4 | 8 | 13.3 |
Northeast | 0 | 0 | 0 | 0 | 1 | 0.7 | 3 | 0.9 | 2 | 3.3 |
Type of primary tumor | ||||||||||
Breast | 5 | 25.0 | 12 | 20.0 | 53 | 35.6 | 73 | 22.6 | 5 | 8.3 |
Colorectal | 4 | 20.0 | 15 | 25.0 | 25 | 16.8 | 38 | 11.8 | 3 | 5.0 |
Prostate | 2 | 10.0 | 7 | 11.7 | 10 | 6.7 | 33 | 10.2 | 2 | 3.3 |
Cervix | 1 | 5.0 | 3 | 5.0 | 16 | 10.7 | 19 | 5.9 | 0 | 0 |
Gastric | 1 | 5.0 | 1 | 1.7 | 8 | 5.4 | 9 | 2.8 | 0 | 0 |
Lung | 0 | 0 | 4 | 6.7 | 3 | 2.0 | 22 | 6.8 | 0 | 0 |
Head and Neck | 0 | 0 | 4 | 6.7 | 2 | 1.3 | 33 | 10.2 | 40 | 66.7 |
Esophageal | 1 | 5.0 | 1 | 1.7 | 4 | 2.7 | 7 | 2.2 | 0 | 0 |
Endometrial | 0 | 0 | 0 | 0 | 2 | 1.3 | 1 | 0.3 | 0 | 0 |
Others | 6 | 30.0 | 13 | 21.7 | 26 | 17.4 | 88 | 27.2 | 10 | 16.7 |
Distant metastasis | ||||||||||
Yes | 11 | 55.0 | 31 | 52.0 | 61 | 41 | 158 | 48.9 | 15 | 25.0 |
No | 9 | 45.0 | 29 | 48.0 | 88 | 59 | 165 | 51.1 | 45 | 75.0 |
Type of current treatment | ||||||||||
Follow-up (NED) | 0 | 0 | 11 | 18.3 | 16 | 10.7 | 45 | 13.9 | 3 | 5.0 |
Curative/Adj/Neoadj systemic therapy | 4 | 20.0 | 18 | 30.0 | 72 | 48.3 | 120 | 37.2 | 45 | 75.0 |
Palliative systemic therapy | 10 | 50.0 | 21 | 35.0 | 56 | 37.6 | 132 | 40.9 | 10 | 16.7 |
Palliative care only | 6 | 30.0 | 10 | 16.7 | 5 | 3.5 | 26 | 8.0 | 2 | 3.3 |
Place of interview | ||||||||||
Ambulatory | 9 | 45.0 | 56 | 93.0 | 117 | 78.5 | 288 | 89.2 | 59 | 98.3 |
Hospital | 11 | 55.0 | 4 | 7.0 | 32 | 21.5 | 35 | 10.8 | 1 | 1.7 |
ECOG performance status | ||||||||||
0–1 | 8 | 40.0 | NA | – | 109 | 73.2 | 220 | 68.8 | 54 | 90.0 |
2–4 | 12 | 60.0 | NA | – | 39 | 26.2 | 100 | 31.3 | 6 | 10.0 |
Missing | 3 | |||||||||